GMT Capital

GMT Capital is a general partner and investment manager for several hedge funds, each managed under the same long-term investment philosophy. They are long-term, value-based, long/short equity investors. The firm works to achieve absolute returns in all markets, measuring itself on the ability to make profitable investments on both sides of the market, long and short. Corporate objectives are, first, long-term wealth creation for their partners and second, integrity and stewardship in all areas, treating their partner capital as they do their own.

Tom Claugus

Founder and President

5 past transactions

Saturn Oil & Gas

Post in 2024
Saturn Oil & Gas Inc is a Canada-based company involved in the exploration and development of oil and natural gas resources. The company specializes in acquiring undervalued, low-risk assets primarily in Alberta and Saskatchewan. Its portfolio includes properties such as Lucky Hills, which features the Viking Formation near Kindersley, and Flaxcombe, located approximately 30 kilometers west of Kindersley. Saturn Oil & Gas generates most of its revenue through the sale of oil, natural gas, and natural gas liquids, primarily operating under variable price contracts. The company aims to advance the exploration and production of its energy assets in these regions.

NewAmsterdam Pharma Company

Post in 2022
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for individuals with metabolic disorders by addressing the shortcomings of currently available treatments. Its leading product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to effectively lower LDL cholesterol levels while potentially overcoming the limitations associated with existing therapies.

AlloVir

Post in 2022
AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.

Bigpoint

Private Equity Round in 2008
Bigpoint GmbH, founded in 2002 and based in Hamburg, Germany, specializes in the development and distribution of online games. Formerly known as e-sport GmbH, the company rebranded in 2007 and has since become a leading player in the gaming industry, recognized as the largest game portal in Germany and among the top three globally. Bigpoint operates under a "free use voluntary payment" model, allowing players of all ages to enjoy high-quality gaming experiences at no initial cost, while offering optional purchases for virtual goods and premium subscriptions. The company is known for its commitment to high standards in technology, gameplay, and entertainment, developing a wide range of games from casual titles to complex multiplayer experiences. With over 500 employees and additional offices in Berlin, San Francisco, and Malta, Bigpoint has garnered several awards for its achievements in the gaming sector.

XAware

Series C in 2008
XAware is an opensource data integration vendor. XAware's tool set leverages a Service Oriented Architecture (SOA) and is built upon key technical standards (such as J2EE, XML, and Eclipse) and industry standards (such as ACORD, CSIO, EDI, HL7 and NIEM).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.